Advances in molecular medicine have led to the development of PARP inhibitors, which have shown great promise in the treatment of a substantial population of patients with ovarian and breast cancer, offering notable benefit over conventional chemotherapy3,4. Here, PARP1 is linked to breast carcinoma.